Clinical trial site network Rare Disease Research (RDR) has announced a strategic partnership with health tech company myTomorrows to enhance the visibility of rare disease trials and facilitate patient referrals from both community and specialist care settings. This collaboration will initially focus on RDR sites in Georgia, Florida, and North Carolina, addressing the significant barriers that rare disease patients often encounter in accessing appropriate clinical trials, such as complex eligibility criteria and limited study availability.

The partnership leverages myTomorrows’ innovative technology, which connects patients, physicians, trial sites, and biopharma companies to streamline the search for clinical trials. By enabling healthcare providers to utilize the myTomorrows platform, they can easily identify relevant RDR trials in their vicinity and submit structured referrals directly to RDR site teams. This structured approach aims to reduce the time RDR teams spend managing mismatched or incomplete requests, allowing them to focus more on supporting patients who are well-suited for active studies. Additionally, patient navigators from myTomorrows will assist families in gathering necessary medical information and reviewing trial options, thereby enhancing the overall referral process.

This partnership signifies a shift towards more efficient patient engagement and operational practices within the clinical trial landscape. By improving the referral process and trial matching, it not only stands to increase patient enrollment in rare disease studies but also enhances the overall experience for patients and healthcare providers alike. As RDR and myTomorrows work together, this model could serve as a blueprint for future initiatives aimed at improving access to clinical trials across various therapeutic areas, ultimately accelerating the development of investigational therapies for rare diseases.

Source: fiercebiotech.com